

# Early Developmental Disruption of Type 2 Deiodinase Pathway in Mouse Skeletal Muscle Does Not Impair Muscle Function

Daniele L. Ignacio,<sup>1,2</sup> Diego H. S. Silvestre,<sup>1–3</sup> Elena Anne-Palmer,<sup>1</sup> Barbara M. L. C. Bocco,<sup>1,4</sup> Tatiana L. Fonseca,<sup>1</sup> Miriam O. Ribeiro,<sup>5</sup> Balázs Gereben,<sup>6</sup> Antonio C. Bianco,<sup>1</sup> and Joao P. Werneck-de-Castro<sup>1–3</sup>

**Background:** Myogenesis is positively regulated by thyroid hormone (triiodothyronine [T3]), which is amplified by the type 2 deiodinase (D2) activation of thyroxine to T3. Global inactivation of the *Dio2* gene impairs skeletal muscle (SKM) differentiation and regeneration in response to muscle injury. Given that newborn and adult mice with late developmental SKM *Dio2* disruption do not develop a significant phenotype, it was hypothesized that D2 plays an early role in this process.

**Methods:** This was tested in mice with SKM disruption of *Dio2* driven by two early developmental promoters: *MYF5* and *MYOD*.

**Results:** MYF5 myoblasts in culture differentiate normally into myotubes, despite loss of almost all D2 activity. *Dio2* mRNA levels in developing SKM obtained from *MYF5-D2KO* embryos (E18.5) were about 54% of control littermates, but the expression of the T3-responsive genes *Myh1* and 7 and *Atp2a1* and 2 were not affected. In *MYF5-D2KO* and *MYOD-D2KO* neonatal hind-limb muscle, the expression of *Myh1* and 7 and *Atp2a2* remained unaffected, despite 60–70% loss in D2 activity and/or mRNA. Only in *MYOD-D2KO* neonatal muscle was there a 40% reduction in *Atp2a1* mRNA. Postnatal growth of both mouse models and SKM function as assessed by exercise capacity and measurement of muscle strength were normal. Furthermore, an analysis of the adult soleus revealed no changes in the expression of T3-responsive genes, except for an about 18% increase in *MYOD-D2KO* SOL *Myh7* mRNA.

**Conclusion:** Two mouse models of early developmental disruption of *Dio2* in myocyte precursor exhibit no significant SKM phenotype.

**Keywords:** myogenesis, thyroid hormone signaling, deiodinases, skeletal muscle function

## Introduction

**S**KELETAL MUSCLE (SKM) is the most abundant tissue in human body mass (~40%). It is an important site of adaptive thermogenesis and plays important roles in energy metabolism (1). A complex transcriptional network orchestrated by myogenic regulatory factors (MRF) that are downstream of the paired domain transcription factors in mice, *Pax3* and *Pax7*, regulates myogenesis (2). MRF are basic helix–loop–helix transcriptional factors implicated in

determination and differentiation of SKM precursors. The first MRF described to be able to induce a myogenic phenotype when transfected to non-myogenic cells (e.g., fibroblasts) was *Myod* (3). Subsequently, a distinct molecule, *Myf5*, was also observed to determine muscle cell lineage (4). Together with *Myf6* (*Mrf4*) and myogenin (*Myog*), they form the MRF family. However, *Myog* is critical in muscle differentiation rather than in determination as the other members of the family are (5,6). Then, myoblasts differentiate into myocytes and ultimately fuse to form mature multinucleated

<sup>1</sup>Division of Endocrinology and Metabolism, Rush University Medical Center, Chicago, Illinois.

<sup>2</sup>Biophysics Institute and School of Physical Education and Sports; <sup>3</sup>Nutrition Institute Josué de Castro; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

<sup>4</sup>Department of Translational Medicine, Federal University of São Paulo, São Paulo, Brazil.

<sup>5</sup>Developmental Disorders Program, Center for Biological and Health Sciences, Mackenzie Presbyterian University, São Paulo, Brazil.

<sup>6</sup>Department of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.

myofiber expressing a set of myofibrillar proteins required for muscle function.

During embryogenesis, *Myf5* is the first MRF to be expressed, followed by *Myod*, pointing to a hierarchy among the MRF (7). The fact that both *MYF5-KO* and *MYOD-KO* mice exhibit normal myogenesis (8,9) and the loss of myogenesis in the double *MYF5/MYOD-KO* mouse (9) suggest that (i) these transcription factors play a redundant role in the same precursor cell or (ii) they are expressed in different precursor cells capable of taking over in the absence of the other (10). Indeed, either the *cre-MYOD* or *cre-MYF5* mouse when crossed with a floxed reporter gene induces expression in virtually all SKM fibers (11,12). However, the parallel model has been challenged recently, indicating that both *Myf5* and *Myod* are expressed in the same precursor cell (13). Thus, cre-driven gene disruption using either *Myf5* or *Myod* targets the muscle precursor cell.

Thyroid hormone (TH) affects myogenesis. The TH triiodothyronine (T3) enters SKM fibers through membrane transporters (MCT8 and MCT10) and diffuses to the nucleus to interact with TH receptors (THR; mainly THR $\alpha$ ) and modulates the expression of specific sets of T3-responsive genes. T3 regulates muscle development, contractility, and metabolism (14,15). The first line of evidence supporting the role of T3 in SKM development came from studies where T3 treatment induced terminal differentiation and increased *Myod* expression in C2 myoblasts (16,17). T3-THR heterodimerizes with the retinoic receptors (RXR) to bind to the thyroid response element (TRE) located in the *Myod* gene (18). The T3-THR-RXR complex also directly regulates *Myog* expression (19). Thus, T3 ceases proliferation and stimulates differentiation in SKM precursor cell.

Normal serum levels of TH are essential to SKM function. Overt hypo- and hyperthyroid patients present SKM-related clinical symptoms characteristic of hypo- and hypermetabolic states, respectively (20–24). Also, subclinical thyroid disease impairs muscle function and/or exercise capacity (25,26). T3 upregulates the expression of fast-twitch SKM proteins, for example systemic hypothyroidism decreases the fast myosin heavy chain 1 and 2 (*Myh1* and 2) genes that encode the MyHC 2X and 2A proteins, respectively) and increases the slow *Myh7* (MyHC 1 protein) (27,28). Furthermore, T3 stimulates the expression of the fast reticulum endoplasmic calcium pump SERCA1a (29) and skeletal alpha-actin (30). In terms of metabolism, T3 positively regulates the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump, GLUT4 (the major glucose transporter in SKM), peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC1 $\alpha$ ), malic enzyme 1, uncoupling protein 3 (UCP3), and glycerol phosphate dehydrogenase- alpha ( $\alpha$ GPD) (31). In humans, >600 genes were modulated in patients under levothyroxine treatment, supporting a broad regulation of the muscle transcriptome by TH (32).

The presence of deiodinases in T3-responsive cells adds a mechanism through which TH action can be customized on a cell-specific fashion at a pre-receptor level (33). Deiodinases are homodimeric selenoenzymes that have a single transmembrane segment connected to a cytosolic globular domain containing the active center embedded in a thioredoxin-like fold (34,35). The type 2 deiodinase (D2) catalyzes the conversion of the pro-hormone thyroxine (T4) into T3. Thus, its presence in cells strengthens the flow of T3 molecules

reaching the nucleus, with the additional T3 produced locally. In contrast, the type 3 deiodinase (D3) attenuates the flow of T3 to the nucleus because it inactivates T3 to 3,5-diiodo-L-thyronine and prevents T4 utilization via inactivation to reverse T3 (14).

Given that D2 is present in human SKM and considering the large muscle mass, it is reasonable to speculate that muscle D2 would play a major role in whole-body metabolism, muscle physiology, and/or development (36), albeit its specific activity is relatively low compared with other D2-expressing tissues such as the pituitary gland, brain, and brown adipose tissue (27). The development of a mouse model of global *Dio2* inactivation (*GLOB-D2KO*) was the first step toward a better understanding of the role played by D2 in several tissues (37). Despite normal levels of T3, the *GLOB-D2KO* mouse is prone to obesity under thermoneutrality, a phenotype attributed to D2 disruption in BAT and/or SKM (38,39). However, disruption of *Dio2* specifically in SKM fibers (*SKM-D2KO*) did not impact body metabolism, challenging the role played by D2 in SKM (40). Also, the *SKM-D2KO* mouse is systemically euthyroid, and the SKM does not exhibit evidence of hypothyroidism with preserved muscle performance (27). This contrasts with the severe muscle hypothyroidism observed in the *GLOB-D2KO* mice (41). An explanation has been the timing of *Dio2* disruption: while the *GLOB-D2KO* mouse lacks *Dio2* in all tissues since early in embryogenesis, the *SKM-D2KO* mouse experiences *Dio2* disruption after the muscle fiber has differentiated (27). Indeed, primary differentiated myotubes and adult SKM of the *GLOB-D2KO* mouse exhibit signs of hypothyroidism and characteristics of a slow-twitch phenotype (i.e., decreased *Myh2* expression) (41,42). In addition, cultures of *GLOB-D2KO* skeletal myocytes fail to differentiate into myotubes, indicating a phenotype of excessive proliferation and impaired differentiation (41).

This study reports that primary myoblasts from *MYF5-D2KO* mouse differentiate into myotubes, but after seven days of differentiation, the phenotype of the myotubes is shifted to a slow-twitch phenotype with a failure to express fully the fast *Myh2* and upregulation of *Myh7*. However, the *MYF5-D2KO* and the *MYOD-D2KO* mice grow normally and exhibit normal exercise capacity and muscle strength. Therefore, muscle function is preserved in both *MYF5-D2KO* and *MYOD-D2KO* mice, indicating that the severe muscle hypothyroidism reported in the *GLOB-D2KO* mouse reflects the lack of D2 in other cell types within SKM, in addition to the myocytes.

## Methods

### Animals

All experimental procedures were planned following the American Thyroid Association guide to investigating TH economy and action in rodent and cell models (43) and approved by the local Institutional Animal Care and Use Committee (IACUC) at Rush University Medical Center. To eliminate *Dio2* expression of SKM precursor cells, the floxed D2 mice were crossed with the cre-recombinase expression driven by *Myf5* (*MYF5-D2KO*) (27) or *Myod* (*MYOD-D2KO*) (11). *Myf5* and *Myod* are members of the muscle regulatory factors that determine myogenesis and are expressed in the same SKM precursor (13). Thus, the *MYOD-D2KO* mouse

model was used to confirm results obtained with the *MYF5-D2KO*. Animals used in the experiments were hemizygous for the cre transgene expression, and the genetic background was C57/B6 for *Floxed-D2* and *Cre-MYF5*, while the *MYOD-D2KO* mouse was generated in the 129SVB strain (11). Newborn (12–24 hours old) or male adult mice (16–24 weeks old) were used in the studies. Animals were kept on a standard chow diet (3.1 kcal/g; 2918 Teklan Global Protein rodent diet) or high-fat diet (HFD; 4.5 kcal/g; TD 95121; Harlan Teklad) for indicated weeks at room temperature (22°C), with a 12 hour dark/light cycle starting at 06:00 h, and were housed in standard plastic cages with four to five mice per cage. *Cre-MLC* littermates were used as controls.

#### *Culture of murine primary SKM cells*

Primary skeletal myoblasts of *MYF5-D2KO* mice (three weeks old) were obtained as previously described (27,44). Briefly, hind-limb muscles were digested in collagenase 0.2%, followed by dispase 2.4 IU/mL and trypsin (0.1%) digestion. After passing through a 70 mm cell strainer, cells were pre-plated in collagen-coated flasks in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum for 2 h to avoid fibroblast contamination. After that, the supernatant was recovered and re-plated. Myoblasts were kept in growth medium at 70% confluence. To evaluate myotube formation and gene expression, cells were differentiated for the indicated times in DMEM containing 2% horse serum. All cultures were supplemented with  $10^{-7}$  M sodium selenite.

#### *Deiodinase assays*

SKM samples were sonicated in phosphate-EDTA buffer (PE) containing 10 mM of dithiothreitol (DTT), 0.25 M of sucrose and protease inhibitor cocktail (Roche). Protein was measured by Bio-Rad protein assay solution, and 200  $\mu$ g were incubated for 3 h at 37°C in the presence of 20 mM of DTT, 1 mM of PTU, 10 nM of T3, 0.1 nM of T4, and 200 K cpm  $^{125}$ I-T4 (PerkinElmer Life and Analytical Sciences, Inc.; # NEX111H500UC). Assays were stopped with the addition of horse serum and 50% TCA and free  $^{125}$ I counted on the 2470 Automatic  $\gamma$  Counter Wizard2 (Perkin-Elmer), as described previously (27). This methodology was validated by Ultra Performance Liquid Chromatography (UPLC) (27).

#### *Hypothyroidism*

Hypothyroidism was induced by an iodine-deficient diet with 0.15% PTU (TD 95125; Harlan Teklad) and 0.05% of methiimadole in drinking water, as described previously (27).

#### *Maximum exercise capacity test and physiological evaluation of muscle strength*

Maximum exercise capacity and plantar flexors strength were evaluated in mice (20–24 weeks old), as previously described (27), and all tests were performed by personnel blind to the genotype. Mice were acclimatized to the treadmill (Columbus Instruments) for five to six consecutive days by running 5–10 min per day at 5–10 m/min. The test started at 10 m/min and the speed increased 2 m/min every 2 min until exhaustion. To assess muscle strength, electrodes were positioned to stimulate the plantar flexors (e.g., soleus and

gastrocnemius muscles). The electric current applied to the muscle was progressively increased until the force developed plateaued at maximum level, which was then used to create a twitch response (1 Hz) and tetanus at 100 Hz. Force was recorded using the DMC software (Aurora Scientific v5.420), and the data were analyzed with DMA software (Aurora Scientific v5.220).

#### *Indirect calorimetry*

Animals were admitted to the comprehensive laboratory animal monitoring system (CLAMS; OXYMAX System 4.93; Columbus Instruments) with free access to food and water, as previously described (40). Animals were allowed to acclimatize in individual metabolic cages for 48 h before the 24 h measurements. This system allows for continuous measurement of oxygen consumption ( $\text{VO}_2$ ; mL/kg BW/h) and carbon-dioxide production ( $\text{VCO}_2$ ). These data were used to calculate the respiratory exchange ratio (RER;  $\text{VCO}_2/\text{VO}_2$ ). The system is always calibrated against a standard gas mix containing defined quantities of  $\text{O}_2$  and  $\text{CO}_2$  before the experiment. Studies were performed at 22°C.

#### *Gene expression analysis*

Total RNA was extracted using RNeasy kits (Qiagen), according to the manufacturer's instructions. DNase treatment (Qiagen) was performed to avoid genomic DNA contamination. The extracted RNA was quantified with a NanoDrop spectrophotometer, and 0.5–1.0  $\mu$ g of total RNA was reverse transcribed into cDNA using a high-capacity cDNA reverse transcription kit (Applied Biosystems). Genes of interest were measured by reverse transcription polymerase chain reaction (RT-PCR; StepOnePlus real-time PCR system, Applied Biosystems) using SYBR Green Supermix (Quanta Biosciences). Standard curves were performed for all gene expression analysis and consisted of four to five points of serially diluted cDNA. SKM PCR primers were designed to span exon–exon boundaries. The coefficient of correlation was  $>0.98$  for all curves, and the amplification efficiency ranged between 80% and 110%. Amplicon specificity was assessed by the melting curve. Cyclophilin A or B was used as an internal control gene, and no significant changes in gene expression of either gene were observed between groups.

#### *Serum hormone measurements*

Blood samples were processed for thyrotropin (TSH), T3, and T4 analysis using a MILLIPLEX rat TH panel kit following the instructions of the manufacturer (Millipore Corp.) and read on a BioPlex (Bio-Rad).

#### *Statistical analysis*


All data are expressed as the mean  $\pm$  standard error of the mean (SEM). Student's *t*-test was used to compare the differences between knockout and control mice in D2 activity, gene expression, exercise capacity, and muscle strength. One-way analysis of variance (ANOVA) was used to compare more than two groups (body weight), and Tukey's correction for multiple comparisons was applied as a *post hoc* test. Oxygen consumption ( $\text{VO}_2$ ) and RER over time were

analyzed by two-way ANOVA followed by Bonferroni's correction. Statistical significance was set at  $p \leq 0.05$ .

## Results

### MYF5-D2KO and MYOD-D2KO animals exhibit normal postnatal growth

The contrasting results obtained from the *GLOB-D2KO* (41) and the *SKM-D2KO* (27,40) led to the hypothesis that D2 plays a major role during SKM development. Two mouse models with *Dio2* inactivation specifically in SKM precursors were studied: *MYF5-D2KO* and *MYOD-D2KO*. Mice were born to the expected Mendelian distribution (Fig. 1A and B), and no differences in body weight were noticed



**FIG. 1.** *MYF5-D2KO* and *MYOD-D2KO* mice grow normally. (A) Number of mice born of each genotype after crossing a *floxed Dio2* heterozygous/*Cre-MYF5*-negative female mouse with a *floxed Dio2* heterozygous/*Cre-MYF5*-positive male mouse. (B) Same as (A) but a *floxed Dio2* heterozygous/*Cre-MYOD*-negative female mouse was crossed with a *floxed Dio2* heterozygous/*Cre-MYOD*-positive male mouse. Numbers above bars denote the relative number of mice born. (C) Body weight of neonatal *MYF5-D2KO* mice; and wild-type *floxed Dio2* and *Cre-MYF5* littermates ( $n = 13-18$ ). (D) Body weight of neonatal (12–24 h) *MYOD-D2KO* mice; and wild-type *floxed Dio2* and *Cre-MYF5* littermates ( $n = 3-9$ ). (E) Body weight growth curve of *MYF5-D2KO* and *Cre-MYF5* mice ( $n = 7-9$ ). (F) Same as (E) but *MYOD-D2KO* and *Cre-MYOD* mice were used ( $n = 6-8$ ). Values are the mean  $\pm$  standard error of the mean (SEM).

(Fig. 1C and D). Also, they gained weight similarly to control littermate mice over a 12-week period (Fig. 1E and F).

### MYF5-D2KO myoblasts fuse into myotubes but exhibit a slow-twitch phenotype

*MYF5-D2KO* myoblasts were obtained from the hind limb of three-week-old *MYF5-D2KO* mice. To understand the role played by D2 specifically in myocyte differentiation, primary *MYF5-D2KO* myoblasts were cultured for seven days. The findings indicated a milder phenotype compared with *GLOB-D2KO*. Despite an 80% loss in *Dio2* expression (Fig. 2B), myotubes were formed in both *Cre-MYF5* and *MYF5-D2KO* differentiated myoblasts (Fig. 2A). However, the phenotype regarding the myosin expression is shifted to a slow-contracting phenotype in the *MYF5-D2KO* myotubes: *Myh2* mRNA levels were about 50% lower, while *Myh7* were 100% increased (Fig. 2B), indicating impaired T3 signaling.

### *Dio2* disruption in developing SKM does not impair muscle-related gene expression


In order to test whether D2 plays a role during embryogenesis, SKM was obtained from *MYF5-D2KO* embryos at day 18.5 of development. *Dio2* mRNA levels were about 54% of the control littermate expression (Fig. 3A). The expression of the TH inactivating enzyme D3 (*Dio3* gene) and the main muscle TRH receptor TRH $\alpha$ 1 were normally expressed in the *MYF5-D2KO* muscles (Fig. 3A). The loss of D2 did not impair the expression of T3-responsive genes *Myh2/7* and *Atp1a1/a2* (which encode the sarcoplasmic reticulum calcium ATPase 1 and 2—SERCA 1/2, respectively).

### TH signaling is preserved in *MYF5-D2KO* and *MYOD-D2KO* neonatal SKM

SKM D2 activity peaks at birth and decreases with age, suggesting a role in postnatal development (27,41). To test whether T3 signaling is affected by neonatal SKM D2 expression, the expression of T3-responsive genes was studied in the neonatal hind-limb muscles of the *MYF5-D2KO* mice. SKM D2 activity was decreased by 70% (Fig. 3B), and *Dio2* expression by 60% (Fig. 3C) in *MYF5-D2KO* muscles. However, *Myh2*, *Atp2a1*, *Myh7*, and *Atp2a2* gene expression was not influenced by the low levels of D2 (Fig. 2D). To confirm the results in the *MYF5-D2KO*, the *MYOD-D2KO* mice were also studied. Similarly, *Dio2* mRNA was diminished by about 60% in neonatal *MYOD-D2KO* hind-limb muscles, and *Atp2a1* was 40% reduced (Fig. 4).

### SKM function is preserved in adult *MYF5-D2KO* mice, despite low D2 expression

Soleus muscle gene expression is dramatically affected by systemic hypothyroidism (Supplementary Fig. S1A; Supplementary Data are available online at [www.liebertpub.com/thy](http://www.liebertpub.com/thy)), with decreased expression of *Myh1*, *Myh2*, *Atp2a1*, and *Myod*, and increased expression of *Myh7* (Supplementary Fig. S1B). Adult *MYF5-D2KO* mice were euthyroid (Table 1), and their soleus exhibited 40–60% reduction in D2 activity and expression (Fig. 5A and B), but there was no change in the expression of T3-responsive genes (Fig. 5B). In addition, *MYF5-D2KO* mice exhibited normal exercise capacity (Fig.




5C) and plantar flexor muscle strength in response to 1–100 Hz stimulation (Fig. 5D). When admitted to the comprehensive laboratory animal monitoring system, the knockout mice exhibited similar  $VO_2$  and RER compared to control mice (Supplementary Fig. S2A–C).

*Adult MYOD-D2KO mouse exhibits mild SKM hypothyroidism but normal performance*


*MYOD-D2KO* mice have normal levels of TSH ( $0.31 \pm 0.02$  vs.  $0.37 \pm 0.07$  ng/mL) in blood, indicating a systemic euthy-

roid state. In *MYOD-D2KO* soleus, *Dio2* expression was  $\sim 40\%$  decreased compared with control littermates (Fig. 6A). *Myh7* expression was upregulated by 20%, whereas *Myh2*, *Atp2a1/a2* mRNA levels were not affected (Fig. 6A). The *MYOD-D2KO* mouse performed similarly in the maximal exercise test as the control littermates (Fig. 6B). Moreover, when the plantar flexor muscles were stimulated at 1–100 Hz, the resulting force was not statistically different between *MYOD-D2KO* and control animals, although there was a trend toward increased strength in *MYOD-D2KO* mice ( $p=0.08$ ; Fig. 6C).



**FIG. 3.** Embryonic and neonatal muscle of *MYF5-D2KO* mice. (A) mRNA levels of indicated genes in skeletal muscle of *Cre-MYF5* and *MYF5-D2KO* embryos (E18.5;  $n=6-8$ ). (B) D2 activity of neonatal skeletal muscle of *Cre-MYF5* and *MYF5-D2KO* mice ( $n=3-8$ ). (C) mRNA levels in neonatal muscle of *Cre-MYF5* and *MYF5-D2KO* mice ( $n=3-8$ ). Values are the mean  $\pm$  SEM. \*\* $p \leq 0.01$ .





**FIG. 4.** Neonatal muscle of *MYOD-D2KO* mice. mRNA levels of indicated genes in neonatal muscle of *Cre-MYF5* and *MYF5-D2KO* mice ( $n=3-8$ ). Values are the mean  $\pm$  SEM. \* $p \leq 0.05$ ; \*\* $p \leq 0.01$ .

## Discussion

The present studies of selective *Dio2* inactivation in skeletal myocytes (i.e., *MYF5-D2KO* and *MYOD-D2KO* mice) indicate that early inactivation of the *Dio2* gene during development only mildly affects SKM when assessed in cultured skeletal myocytes and does not cause a notable phenotype in mice. This is unexpected given previous data in mice with global *Dio2* inactivation (41). It is conceivable that, as in the brain (45), residual D2 expression in other SKM cells act paracrinally and supply sufficient T3 to the developing skeletal myocyte, minimizing *Dio2* inactivation.

D2 activity is very low in primary cultures of myoblasts but increases during differentiation (42). Similar findings were observed in C2C12 myoblasts and muscle-derived stem cells (41), suggesting that the surge in D2-generated T3 drives muscle differentiation. However, data in cells obtained from different mouse models led to conflicting results. Muscle-derived stem cells of *GLOB-D2KO* mice do not differentiate in myotubes, resulting in no *Myod*, *Myog*, and *Myh2* expression (41). Furthermore, silencing *Dio2* in C2C12 myoblasts arrested cells in a proliferative state (41). In contrast, previous studies have observed normal myotube formation in *GLOB-D2KO* myoblasts and upregulation of slow *Troponin I* and *Myh7* (42). Even knockdown of *THRα* in C2C12 and primary myoblasts only reduces (by 50–60%) but does not abolish the myotubes fusion index and *Serca1* expression (46). It is not clear whether this is a consequence of impaired cell proliferation and/or differentiation seen in *THRαKO* cells. In agreement, the present study reports that primary *MYF5-D2KO* myoblasts fuse normally into myotubes. However, the phenotype is shifted from a fast-twitch

footprint to a slow-twitch phenotype with down regulation of *Myh2* and upregulation of *Myh7* (Fig. 2A and B). Thus, decreasing T3 signaling by disrupting intracellular T4 to T3 conversion or *THR* expression impairs differentiation and gene expression to a certain extent but does not seem to affect myotube formation.

In mice, TH positively regulates the expression of two MRFs, *Myod* and *Myog*, suggesting that T3 promotes SKM differentiation. Disrupting both *THRα1* and  $\beta$  results in a typical hypothyroid phenotype, with an increase in the expression of *Myh7* concomitantly with a reduction in the fast myosins (47), and the *THRα1PV* mice expressing a dominant negative *TRα1* exhibit smaller *Myh2*<sup>+</sup> myofibers (fast-twitch fibers). Studies in the *GLOB-D2KO* mouse indicate that *Dio2* inactivation also causes important disruption of TH signaling in SKM, given that *GLOB-D2KO* neonatal (P1) mice exhibit decreased levels of T3-regulated genes in SKM (41). This is likely to take place during early phases of SKM differentiation, given that selective disruption of *Dio2* in the *SKM-D2KO* mouse resulted in normal neonatal and mature SKM fibers (27). To analyze the role played by *Dio2* in early SKM differentiation, it seemed logical in the present investigation to disrupt *Dio2* in SKM precursors driven by the expression of early MRFs (i.e., *Myf5* and *Myod*) (11,12). Unexpectedly, no major changes in the expression of key T3-responsive genes were observed in SKM of newborn or adult mice of either strain (Figs. 3–6).

SKM contractile capacity is a key endpoint when studying muscle function. SKM capacity was assessed at the age of 20–24 weeks through a maximal exercise capacity protocol, and muscle twitch force (1 Hz) and maximal strength (Tetanic force at 100 Hz) were also measured. In both approaches, *MYF5-D2KO* and *MYOD-D2KO* mice performed similarly to control littermates, indicating normal SKM function (Figs. 5 and 6). Young adult (10–12 weeks old) *GLOB-D2KO* mice exhibited a normal motor phenotype (48,49), but older *GLOB-D2KO* mice (24 weeks old) exhibited abnormal locomotion patterns (49). It is not clear whether this was caused by reduced brain T3 content and abnormal neural control of locomotion. In contrast, disruption of *TRα1* (main isoform found in SKM) induced 20–40% longer contraction and relaxation times of twitches and tetani in soleus muscles compared with wild-type controls, which is explained by the reduced expression of the fast-type sarcoplasmic reticulum Ca-ATPase (*SERCa1*) (50).


The differences in the role of D2 *in vitro* and *in vivo* could be explained by the nature of the two experimental approaches. In the cell culture setup, D2-generated T3 binds to *THR* and/or effluxes to the culture medium. This increases T3 concentration in the medium, which can enter back into the myocytes and promote T3 signaling. Thus, the cell culture setting lends itself to maximize the role played by the D2 pathway. This is not the case *in vivo*, given that D2-generated T3 equilibrates with plasma and the systemic circulation before it can re-enter the skeletal myocytes and promote TH signaling. Therefore, it is not surprising that a more significant phenotype is observed in the cell culture system.

The present results indicate that D2 is not a critical factor for SKM development and/or function. This is in agreement with previous observations that T3 signaling is not affected by *Dio2* inactivation in the adult SKM (27). However, a number of physiological stimuli and conditions are known to regulate D2 expression and activity in SKM such as physical


**TABLE 1.** SERUM LEVELS OF T3, T4, AND TSH OF *CRE-MYF5* AND *MYF5-D2KO* MICE

	T3 (ng/mL)	T4 (ng/mL)	TSH (ng/mL)
<i>Cre-MYF5-D2KO</i>	8.94 $\pm$ 0.68	85.94 $\pm$ 25.63	0.72 $\pm$ 0.17
<i>MYF5-D2KO</i>	10.38 $\pm$ 0.44	63.08 $\pm$ 8.2	0.67 $\pm$ 0.15

Values are the mean  $\pm$  standard error of the mean. T3, triiodothyronine; T4, thyroxine; TSH, thyrotropin.



**FIG. 5.** Adult soleus (SOL) D2 activity, gene expression and skeletal muscle function of *Cre-MYF5* and *MYF5-D2KO* mice. (A) D2 activity of adult SOL muscle ( $n=5$ ). (B) *Dio2* and selected triiodothyronine (T3)-responsive genes mRNA levels in SOL ( $n=9-11$ ). (C) Exercise time and maximum speed ( $S_{max}$ ) achieved on the treadmill maximal exercise test. (D) Maximal force (100 Hz;  $F_{max}$ ) and twitch force (1 Hz) of electrically stimulated plantar flexors (e.g., soleus and gastrocnemius muscles) normalized by body weight. Values are the mean  $\pm$  SEM. \* $p \leq 0.05$ ; \*\* $p \leq 0.01$  vs. *Cre-MYF5*.



**FIG. 6.** Adult SOL gene expression and skeletal muscle function of *Cre-MYOD* and *MYOD-D2KO* mice. (A) *Dio2* and selected T3-responsive genes mRNA levels in SOL muscle ( $n=6$ ). (B) Exercise time and maximum speed ( $S_{max}$ ) achieved on the treadmill maximal exercise test. (C) Maximal force (100 Hz;  $F_{max}$ ) and twitch force (1 Hz) of electrically stimulated plantar flexors (e.g., soleus and gastrocnemius muscles) normalized by body weight. Values are the mean  $\pm$  SEM. \* $p \leq 0.05$  vs. *Cre-MYOD*.

exercise, IGF-1, insulin and insulin sensitizers, fasting, muscle injury, and inflammation, which could be associated with physiological consequences (41,42,51–54). For example, disruption of *Dio2* in SKM fibers (*SKM-D2KO* mouse) impairs the acute and chronic exercise-induced *PGC1a* expression and mitochondria content (51).

In conclusion, *Dio2* inactivation in differentiating myoblasts changes its phenotype but does not interfere with myoblast fusion. In addition, disruption of D2-mediated T3 production in SKM precursor cell does not impair muscle development and muscle function *in vivo*.

### Acknowledgments

This work was supported by NIDDK (R01 65055—A.C.B.), Brazilian National Research Council (CNPq; 202189/2011-2—J.P.W.C. and fellowship to D.L.I.), American Thyroid Association (ATA; M1301627—J.P.W.C.), and Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ—J.P.W.C.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Author Disclosure Statement

All authors declare that no competing financial interests exist.

### References

- Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR 2014 Thyroid hormones and skeletal muscle—new insights and potential implications. *Nat Rev Endocrinol* **10**:206–214.
- Moncaut N, Rigby PW, Carvajal JJ 2013 Dial M(RF) for myogenesis. *FEBS J* **280**:3980–3990.
- Davis RL, Weintraub H, Lassar AB 1987 Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* **51**:987–1000.
- Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH 1989 A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. *EMBO J* **8**:701–709.
- Megeney LA, Rudnicki MA 1995 Determination versus differentiation and the MyoD family of transcription factors. *Biochem Cell Biol* **73**:723–732.
- Kassar-Duchossoy L, Gayraud-Morel B, Gomes D, Rocancourt D, Buckingham M, Shinin V, Tajbakhsh S 2004 *Mrf4* determines skeletal muscle identity in *Myf5*:*Myod* double-mutant mice. *Nature* **431**:466–471.
- Ott MO, Bober E, Lyons G, Arnold H, Buckingham M 1991 Early expression of the myogenic regulatory gene, *myf-5*, in precursor cells of skeletal muscle in the mouse embryo. *Development* **111**:1097–1107.
- Rudnicki MA, Braun T, Hinuma S, Jaenisch R 1992 Inactivation of *MyoD* in mice leads to up-regulation of the myogenic HLH gene *Myf-5* and results in apparently normal muscle development. *Cell* **71**:383–390.
- Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R 1993 *MyoD* or *Myf-5* is required for the formation of skeletal muscle. *Cell* **75**:1351–1359.
- Haldar M, Karan G, Tvrdik P, Capecchi MR 2008 Two cell lineages, *myf5* and *myf5*-independent, participate in mouse skeletal myogenesis. *Dev Cell* **14**:437–445.
- Chen JC, Mortimer J, Marley J, Goldhamer DJ 2005 *MyoD*-cre transgenic mice: a model for conditional mutagenesis and lineage tracing of skeletal muscle. *Genesis* **41**:116–121.
- Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scime A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM 2008 PRDM16 controls a brown fat/skeletal muscle switch. *Nature* **454**:961–967.
- Comai G, Sambasivan R, Gopalakrishnan S, Tajbakhsh S 2014 Variations in the efficiency of lineage marking and ablation confound distinctions between myogenic cell populations. *Dev Cell* **31**:654–667.
- Arrojo EDR, Fonseca TL, Werneck-de-Castro JP, Bianco AC 2013 Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. *Biochim Biophys Acta* **1830**:3956–3964.
- Brent GA 2012 Mechanisms of thyroid hormone action. *J Clin Invest* **122**:3035–3043.
- Carnac G, Albagli-Curiel O, Vandromme M, Pinset C, Montarras D, Laudet V, Bonniou A 1992 3,5,3'-Triiodothyronine positively regulates both *MyoD1* gene transcription and terminal differentiation in C2 myoblasts. *Mol Endocrinol* **6**:1185–1194.
- Hughes SM, Taylor JM, Tapscott SJ, Gurley CM, Carter WJ, Peterson CA 1993 Selective accumulation of *MyoD* and myogenin mRNAs in fast and slow adult skeletal muscle is controlled by innervation and hormones. *Development* **118**:1137–1147.
- Muscat GE, Mynett-Johnson L, Dowhan D, Downes M, Griggs R 1994 Activation of *myoD* gene transcription by 3,5,3'-triiodo-L-thyronine: a direct role for the thyroid hormone and retinoid X receptors. *Nucl Acids Res* **22**:583–591.
- Downes M, Griggs R, Atkins A, Olson EN, Muscat GE 1993 Identification of a thyroid hormone response element in the mouse myogenin gene: characterization of the thyroid hormone and retinoid X receptor heterodimeric binding site. *Cell Growth Differ* **4**:901–909.
- Khaleeli AA, Gohil K, McPhail G, Round JM, Edwards RH 1983 Muscle morphology and metabolism in hypothyroid myopathy: effects of treatment. *J Clin Pathol* **36**:519–526.
- Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS 2006 Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. *J Clin Endocrinol Metab* **91**:4650–4656.
- Khaleeli AA, Griffith DG, Edwards RH 1983 The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. *Clin Endocrinol* **19**:365–376.
- Mastaglia FL, Ojeda VJ, Sarnat HB, Kakulas BA 1988 Myopathies associated with hypothyroidism: a review based upon 13 cases. *Aust N Z J Med* **18**:799–806.
- Erkintalo M, Bendahan D, Mattei JP, Fabreguettes C, Vague P, Cozzzone PJ 1998 Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by *in vivo* phosphorus-31 magnetic resonance spectroscopy. *Metabolism* **47**:769–776.
- Caraccio N, Natali A, Sironi A, Baldi S, Frascerra S, Dardano A, Monzani F, Ferrannini E 2005 Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. *J Clin Endocrinol Metab* **90**:4057–4062.



26. Monzani F, Caraccio N, Siciliano G, Manca L, Murri L, Ferrannini E 1997 Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. *J Clin Endocrinol Metab* **82**:3315–3318.
27. Werneck-de-Castro JP, Fonseca TL, Ignacio DL, Fernandes GW, Andrade-Feraud CM, Larrey LJ, Ribeiro MB, Ribeiro MO, Gereben B, Bianco AC 2015 Thyroid hormone signaling in male mouse skeletal muscle is largely independent of D2 in myocytes. *Endocrinology* **156**:3842–3852.
28. Schiaffino S, Reggiani C 2011 Fiber types in mammalian skeletal muscles. *Physiol Rev* **91**:1447–1531.
29. van der Linden CG, Simonides WS, Muller A, van der Laarse WJ, Vermeulen JL, Zuidwijk MJ, Moorman AF, van Hardeveld C 1996 Fiber-specific regulation of Ca(2+)-ATPase isoform expression by thyroid hormone in rat skeletal muscle. *Am J Physiol* **271**:C1908–1919.
30. Collie ES, Muscat GE 1992 The human skeletal alpha-actin promoter is regulated by thyroid hormone: identification of a thyroid hormone response element. *Cell Growth Differ* **3**:31–42.
31. Simonides WS, van Hardeveld C 2008 Thyroid hormone as a determinant of metabolic and contractile phenotype of skeletal muscle. *Thyroid* **18**:205–216.
32. Visser WE, Heemstra KA, Swagemakers SM, Ozgur Z, Corssmit EP, Burggraaf J, van Ijcken WF, van der Spek PJ, Smit JW, Visser TJ 2009 Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. *J Clin Endocrinol Metab* **94**:3487–3496.
33. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A, Bianco AC 2008 Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev* **29**:898–938.
34. Callebaut I, Curcio-Morelli C, Mornon JP, Gereben B, Buettner C, Huang S, Castro B, Fonseca TL, Harney JW, Larsen PR, Bianco AC 2003 The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure. *J Biol Chem* **278**:36887–36896.
35. Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeold A, Curcio-Morelli C, Harney JW, Luongo C, Mulcahey MA, Larsen PR, Huang SA, Bianco AC 2008 The thyroid hormone-inactivating deiodinase functions as a homodimer. *Mol Endocrinol* **22**:1382–1393.
36. Salvatore D, Bartha T, Harney JW, Larsen PR 1996 Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. *Endocrinology* **137**:3308–3315.
37. Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA 2001 Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. *Mol Endocrinol* **15**:2137–2148.
38. Castillo M, Hall JA, Correa-Medina M, Ueta C, Won Kang H, Cohen DE, Bianco AC 2011 Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality. *Diabetes* **60**:1082–1089.
39. Marsili A, Aguayo-Mazzucato C, Chen T, Kumar A, Chung M, Lunsford EP, Harney JW, Van-Tran T, Gianetti E, Ramadan W, Chou C, Bonner-Weir S, Larsen PR, Silva JE, Zavacki AM 2011 Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity. *PLoS One* **6**:e20832.
40. Fonseca TL, Werneck-De-Castro JP, Castillo M, Bocco BM, Fernandes GW, McAninch EA, Ignacio DL, Moises CC, Ferreira AR, Gereben B, Bianco AC 2014 Tissue-specific inactivation of type 2 deiodinase reveals multilevel control of fatty acid oxidation by thyroid hormone in the mouse. *Diabetes* **63**:1594–1604.
41. Dentice M, Marsili A, Ambrosio R, Guardiola O, Sibilio A, Paik JH, Minchiotti G, DePinho RA, Fenzi G, Larsen PR, Salvatore D 2011 The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. *J Clin Invest* **120**:4021–4030.
42. Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW 2009 Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. *Endocrinology* **150**:1976–1983.
43. Bianco AC, Anderson G, Forrest D, Galton VA, Gereben B, Kim BW, Kopp PA, Liao XH, Obregon MJ, Peeters RP, Refetoff S, Sharlin DS, Simonides WS, Weiss RE, Williams GR 2014 American thyroid association guide to investigating thyroid hormone economy and action in rodent and cell models. *Thyroid* **24**:88–168.
44. Gharaibeh B, Lu A, Tebbets J, Zheng B, Feduska J, Crisan M, Peault B, Cummins J, Huard J 2008 Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. *Nat Protoc* **3**:1501–1509.
45. Freitas BC, Gereben B, Castillo M, Kallo I, Zeold A, Egri P, Liposits Z, Zavacki AM, Maciel RM, Jo S, Singru P, Sanchez E, Lechan RM, Bianco AC 2010 Paracrine signaling by glial cell-derived triiodothyronine activates neuronal gene expression in the rodent brain and human cells. *J Clin Invest* **120**:2206–2217.
46. Milanese A, Lee JW, Kim NH, Liu YY, Yang A, Sedrakyan S, Kahng A, Cervantes V, Tripuraneni N, Cheng SY, Perin L, Brent GA 2016 Thyroid hormone receptor alpha plays an essential role in male skeletal muscle myoblast proliferation, differentiation, and response to injury. *Endocrinology* **157**:4–15.
47. Yu F, Gothe S, Wikstrom L, Forrest D, Vennstrom B, Larsson L 2000 Effects of thyroid hormone receptor gene disruption on myosin isoform expression in mouse skeletal muscles. *Am J Physiol Regul Integr Comp Physiol* **278**:R1545–R1554.
48. Galton VA, Wood ET, St Germain EA, Withrow CA, Aldrich G, St Germain GM, Clark AS, St Germain DL 2007 Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. *Endocrinology* **148**:3080–3088.
49. Barez-Lopez S, Bosch-Garcia D, Gomez-Andres D, Pulido-Valdeolivas I, Montero-Pedraza A, Obregon MJ, Guadano-Ferraz A 2014 Abnormal motor phenotype at adult stages in mice lacking type 2 deiodinase. *PLOS ONE* **9**:e103857.
50. Johansson C, Lannergren J, Lunde PK, Vennstrom B, Thoren P, Westerblad H 2000 Isometric force and endurance in soleus muscle of thyroid hormone receptor-alpha(1)- or -beta-deficient mice. *Am J Physiol Regul Integr Comp Physiol* **278**:R598–603.
51. Bocco BM, Louzada RA, Silvestre DH, Santos MC, Anne-Palmer E, Rangel IF, Abdalla S, Ferreira AC, Ribeiro MO, Gereben B, Carvalho DP, Bianco AC, Werneck-de-Castro JP 2016 Thyroid hormone activation by type-2 deiodinase

- mediates exercise-induced PGC-1 $\alpha$  expression in skeletal muscle. *J Physiol* **594**:5255–5269.
52. Lartey LJ, Werneck-de-Castro JP, O’Sullivan I, Unterman TG, Bianco AC 2015 Coupling between nutrient availability and thyroid hormone activation. *J Biol Chem* **290**:30551–30561.
53. Marsili A, Tang D, Harney JW, Singh P, Zavacki AM, Dentice M, Salvatore D, Larsen PR 2011 Type II iodothyronine deiodinase provides intracellular 3,5,3’-triiodothyronine to normal and regenerating mouse skeletal muscle. *Am J Physiol Endocrinol Metab* **301**:E818–824.
54. Bloise FF, van der Spek AH, Surovtseva OV, Ortiga-Carvalho TM, Fliers E, Boelen A 2016 Differential effects

of sepsis and chronic inflammation on diaphragm muscle fiber type, thyroid hormone metabolism, and mitochondrial function. *Thyroid* **26**:600–609.

Address correspondence to:

*João Pedro Werneck-de-Castro, PhD*  
*Department of Endocrinology and Metabolism*  
*Rush University Medical Center*  
*1735 W. Harrison St., Suite 363*  
*Cohn Building*  
*Chicago, IL 60612*

*E-mail: joaopedrowerneck@yahoo.com.br*

**This article has been cited by:**

1. Anne H. van der Spek, Eric Fliers, Anita Boelen. 2017. The classic pathways of thyroid hormone metabolism. *Molecular and Cellular Endocrinology* . [[CrossRef](#)]